Detalhe da pesquisa
1.
Mass Spectrometry-Based Assessment of M-protein in Peripheral Blood During Maintenance Therapy in Multiple Myeloma.
Blood
; 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38713888
2.
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study.
Br J Haematol
; 2024 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38504552
3.
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
Blood
; 139(4): 492-501, 2022 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34269818
4.
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN.
Am J Hematol
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38622840
5.
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
Lancet Oncol
; 24(2): 139-150, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36642080
6.
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial.
Br J Haematol
; 203(5): 792-802, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37691005
7.
Measurable residual disease in peripheral blood in myeloma: dream or reality.
Curr Opin Oncol
; 35(6): 574-580, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37621165
8.
Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice.
Haematologica
; 108(8): 2192-2204, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36546453
9.
A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.
Eur J Haematol
; 110(5): 564-570, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36726221
10.
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
Lancet Oncol
; 23(1): 65-76, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34871550
11.
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Lancet
; 398(10297): 314-324, 2021 07 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34175021
12.
Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma.
Oncologist
; 27(7): e589-e596, 2022 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35462406
13.
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
Blood
; 136(22): 2513-2523, 2020 11 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-32735641
14.
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
Blood
; 136(8): 936-945, 2020 08 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32325490
15.
A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study.
Future Oncol
; 18(40): 4443-4456, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36799429
16.
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
Lancet
; 395(10218): 132-141, 2020 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31836199
17.
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
N Engl J Med
; 378(6): 518-528, 2018 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29231133
18.
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Blood
; 134(5): 421-431, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31113777
19.
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial.
BMC Cancer
; 21(1): 659, 2021 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34078314
20.
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
Br J Haematol
; 186(4): 549-560, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31124580